The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...
The Georgia Virtual Blood Cancer Conference is Saturday!
The Georgia/South Carolina Region of The Leukemia & Lymphoma Society is proud to present this free VIRTUAL education event to blood cancer patients, survivors, family members, caregivers and healthcare professionals*. Experts in the areas of blood cancer research, treatment, and survivorship will present information on each topic. Our goal is to educate conference participants about treatment options, emerging therapies, management of survivorship issues and LLS resources.
*This is NOT a continuing education (CE) program